

Table 1: MAY2013-01-01 (MUC1 Colon) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
CELLS	Screen	1.66	1.01
	Week 2	1.61	1.01
	Week 10	1.77	1.00
	Week 12	1.82	1.01
	Week 52	1.75	1.01
	Week 55	1.71	1.00
	Week 156	1.58	1.02
PLASMA	Screen	1.04	1.18
	Week 2	1.02	1.21
	Week 10	1.00	1.22
	Week 12	1.00	1.29
	Week 52	1.00	1.30
	Week 55	1.02	1.33
	Week 156	1.02	1.57

Table 2a: MAY2016-07-01 (Erlotinib HCL Duodenum) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	Baseline - Ext / Baseline -Int	9.18	1.00
	Month 3 - Ext / Month 3 - Int	8.85	1.00
	Month 6 - Ext / Month 6 - Int	8.93	1.00
	ET - Ext	9.00	1.00
SERUM	Baseline - Ext / Baseline -Int	3.85	1.00
	Month 3 - Ext / Month 3 - Int	3.90	1.00
	Month 6 - Ext / Month 6 - Int	3.81	1.00
	ET - Ext	4.00	1.00
URINE	Baseline - Ext / Baseline -Int	1.01	43.69
	Month 3 - Ext / Month 3 - Int	1.00	47.51
	Month 6 - Ext / Month 6 - Int	1.00	43.46
	ET - Ext	1.00	50.00
WBC	Baseline - Ext / Baseline -Int	1.01	0.97
	Month 3 - Ext / Month 3 - Int	1.00	0.79
	Month 6 - Ext / Month 6 - Int	1.00	0.89
	ET - Ext	1.00	1.40

		Number of Slides by Subject
		Mean
Material Type	Visit	
TISSUE	Baseline - Ext / Baseline -Int	7.35
	Month 6 - Ext / Month 6 - Int	7.62
	ET - Ext	10.00

**Table 3: NWU2013-01-03 (Telapristone Breast) Average vial count and vial volume per subject, visit, and material type**

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
BUFFY CT	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	1.47	0.50
	Time Point #2 Intervention Time Point	1.00	0.50
	Time Point #3 Study Visit 1 Time Point	1.00	0.50
PLASMA	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	3.28	0.99
	Time Point #2 Intervention Time Point	3.00	1.00
	Time Point #3 Study Visit 1 Time Point	1.24	0.56
SERUM	Time Point #1 Screening Visits 1 and 2, Pregnancy Test Visit	3.05	0.89
	Time Point #2 Intervention Time Point	3.00	0.83
	Time Point #3 Study Visit 1 Time Point	2.53	0.85

**Table 4: NWU2017-09-01 (NWU-Endoxifen Breast) Average vial count and vial volume per subject, visit, and material type**

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
BUFFY CT	EDB Baseline	2.28	0.88
	EDB Visit 2	2.31	0.83
PLASMA	EDB Baseline	11.88	0.91
	EDB Visit 2	10.14	0.87

Table 5a: UW12013-00-01 (Pomegranate Prostate) Average vial count and vial volume per subject, visit, and material type

		Number of Vials by Subject	Average Vial Volume (ml (cc)) by Subject
		Mean	Mean
Material Type	Visit		
PLASMA	PGP Baseline	6.86	0.97
	WEEK 13	6.78	0.96
	WEEK 26	6.81	1.00
	WEEK 39	6.81	0.98
	WEEK 52	6.81	0.96
SERUM	PGP Baseline	4.00	0.67
	WEEK 13	2.00	0.59
	WEEK 26	3.85	0.69
	WEEK 39	2.08	0.69
	WEEK 52	3.96	0.79
URINE	PGP Baseline	2.93	1.00
	WEEK 13	2.89	1.00
	WEEK 26	2.85	1.00
	WEEK 39	2.88	1.00
	WEEK 52	2.89	1.00

**Table 5b: UWI2013-00-01 (Pomegranate Prostate) Average slide count for TISSUE**

		Number of Slides by Subject
		Mean
Material Type	Visit	
TISSUE	PGP Baseline	22.54
	WEEK 52	19.46